Settlement payments are accelerated for certain changes to control operations or the sale of JUZTAPID or MYALEPT® of assets. Aegerion entered into a civil settlement of the False Claims Act (and related government comparisons) and agreed to pay $28.8 million to resolve four discrete categories of covered behaviour: (1) to improperly induce patients to purchase juxtapide by passing donations to a non-profit patient aid organization that participated in the creation of the fund , and to define the coverage criteria to facilitate payments to Juxtapid; (2) distribution of juxtapid for uses that go beyond “medically recognized indications” and are therefore not refundable by public health programs; (3) provide false and misleading information about the safe and effective use of juxtapid that circumvented the REMS required by the FDA; and (4) the provision (and training of physicians) in previous authorization forms and medical necessity letters made available to health insurance funds. Two elements of the transaction – the Complaint Agreement and the FDA Approval Order – resolve the liability of Aegerion`s FDCA. The actual basis of this liability is set out in information accusing two separate offences of the FDCA. These preliminary policy opinions with the DOJ and the SEC are an important step forward in addressing the immediate issues facing Aegerion and positioning the company for value added and short-term growth. As a company, we are very committed to complying with legal and legal provisions and we have made considerable investments to ensure that these values reach our entire organisation. We look forward to leaving these issues behind and continuing our focused efforts to develop and commercialize innovative therapies for patients with debilitating rare diseases. The agreement provides in principle that Aegerion will pay a fine of $40 million, payable over a five-year period, with interest of 1.75% per year. The breakdown of payments is likely to be as follows: approximately $3 million after the closing of the transaction with the DOJ and the SEC, approximately $3.7 million per year (payable quarterly) in the first three years of the five-year payment and approximately $13 million per year (also payable quarterly) in years four and five. Apart from the practices admitted as part of the admission of guilt and agreement with the adjourned proceedings, the claims that were settled in the civil transaction are merely allegations and no evidence of liability has been made. 1 The Company also responded to the Securities and Exchange Commission`s (SEC) allegations regarding the Company`s disclosure practices. SEC billing is outside the scope of this customer alert. September 22, 2017, Aegerion Pharmaceuticals has launched a thorough Investigation by the Department of Justice (DOJ) into the company`s U.S.

business activities regarding Juxtapid, an anti-lipid drug used to treat homozygotic familial hypercholesterolemia (HoFH).1 As described below, DOJ has relied on a number of statutes and a complex web of agreements to address a wide range of allegedly objectionable behavior. , including: Finally, Aegerion will enter into a non-monetary approval order with the FDA, which prohibits future violations of the law.